#HVO hVIVO PLC – Annual Report and Notice of AGM April 28, 2023 – Posted in: hVIVO (HVO) – Tags: agm, clinical, contract, disease, HVO, infection, report, research, respiratory, trials
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today.
The 2022 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com.
The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 23 May 2023 at 11 am.
For further information please contact:
|
hVIVO plc |
+44 (0) 20 7756 1300 |
||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
|||
|
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
|
Ben Cryer, Edward Mansfield, Phil Walker, Will King |
|||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) |
|||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell, Niall Gilchrist |
|||
|
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / |
+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
||